SNS-314 is primarily investigated for its potential in cancer therapy, particularly as a selective inhibitor of Aurora kinases. These kinases play a crucial role in cell division, and their dysregulation is often associated with tumor growth. By targeting Aurora kinases, SNS-314 aims to disrupt the proliferation of cancer cells, making it a promising candidate for treating various types of cancers. Research focuses on its efficacy in preclinical models, with the goal of advancing it into clinical trials for evaluating its safety and effectiveness in human patients. Its application could provide a novel approach to managing cancers that are resistant to conventional therapies.